Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

RepliCel Life Sciences Inc

Healthcare CA RP

0.015CAD
0.00(0%)

Last update at 2025-02-28T20:58:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.010.10
LowHigh

Fundamentals

  • Previous Close 0.01
  • Market Cap1.30M
  • Volume269000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.81931M
  • Revenue TTM0.35M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM 0.35M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -0.31173M -0.74323M -4.07332M -1.58028M -3.00416M
Minority interest - - - - -
Net income -0.31173M -0.74323M -4.07332M -1.58028M -3.00416M
Selling general administrative 1.21M 1.13M 1.51M 0.88M 1.08M
Selling and marketing expenses - - - - -
Gross profit 0.35M 0.35M 0.35M 0.35M 0.35M
Reconciled depreciation 0.00141M 0.00084M 0.00115M 0.00157M 0.00217M
Ebit -1.38625M -0.19144M -3.17184M -1.14438M -2.88281M
Ebitda -1.38478M -0.19060M -3.17069M -1.14280M -2.88064M
Depreciation and amortization 0.00147M 0.00084M 0.00115M 0.00157M 0.00217M
Non operating income net other - - - - -
Operating income -1.38625M -0.19144M -3.17184M -1.14438M -2.88281M
Other operating expenses 1.74M 1.75M 2.65M 1.68M 3.28M
Interest expense 0.15M 0.00670M 0.00553M 0.18M 0.14M
Tax provision - - - - -
Interest income 0.00072M 0.00004M 0.00007M 0.00036M 0.09M
Net interest income -0.00108M -0.00666M 0.00007M -0.17573M -0.09201M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.00000M 1.21M -0.86789M 0.18M 0.04M
Total revenue 0.35M 0.35M 0.35M 0.35M 0.35M
Total operating expenses 1.74M 1.75M 2.65M 1.68M 3.28M
Cost of revenue 0.00147M - - - -
Total other income expense net 1.07M 0.66M -1.76937M -0.25238M -0.07732M
Discontinued operations - - - - -
Net income from continuing ops -0.06929M -0.74323M -4.07332M -1.58028M -2.95375M
Net income applicable to common shares - - -4.07332M -1.58028M -3.00416M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 0.29M 0.80M 0.59M 0.42M 0.42M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.05M - - - -
Total liab 4.82M 6.71M 7.43M 5.48M 3.35M
Total stockholder equity -4.53088M -5.91526M -6.84238M -5.06117M -2.93012M
Deferred long term liab - - - - -
Other current liab 0.24M 0.69M 0.35M 0.35M 0.35M
Common stock 33.12M - 30.29M 28.47M 27.53M
Capital stock - 31.66M 30.29M 28.47M 28.96M
Retained earnings -43.28660M -42.97487M -42.23164M -38.15833M -36.57804M
Other liab - - 5.73M 3.21M 3.38M
Good will - - - - -
Other assets 0.00000M - 0.20M 0.23M 0.27M
Cash 0.06M 0.41M 0.22M 0.03M 0.02M
Cash and equivalents - - - - -
Total current liabilities 1.82M 2.07M 1.67M 2.24M 1.55M
Current deferred revenue 0.35M - - - -
Net debt 0.75M - - 0.04M -
Short term debt 0.81M - - - -
Short long term debt - - - 0.05M -
Short long term debt total 0.81M - - - -
Other stockholder equity 5.64M - - - -
Property plant equipment - - 0.00328M 0.00443M 0.00600M
Total current assets 0.16M 0.64M 0.39M 0.19M 0.23M
Long term investments - - - - -
Net tangible assets - - -6.84238M -5.06117M -4.42589M
Short term investments 0.02M 0.02M 0.02M 0.02M 0.03M
Net receivables 0.04M - 0.06M 0.06M 0.05M
Long term debt - 0.04M 0.03M 0.03M -
Inventory - - - - -
Accounts payable 0.42M - 0.60M 1.06M 0.64M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.13M 0.16M 0.20M 0.24M 0.20M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments - 0.00000M -0.01150M 0.01M -0.02875M
Change to liabilities - - -0.30371M 0.87M 0.03M
Total cashflows from investing activities - - - 0.01M -0.02875M
Net borrowings - - - 0.11M 0.11M
Total cash from financing activities 1.06M 1.60M 2.70M 0.76M 0.42M
Change to operating activities - - -0.02053M 0.05M 0.42M
Net income -0.31173M -0.74323M -4.07332M -1.58028M -3.00416M
Change in cash -0.35386M 0.19M 0.19M 0.01M -2.39459M
Begin period cash flow 0.41M 0.22M 0.03M 0.02M 2.42M
End period cash flow 0.06M 0.41M 0.22M 0.03M 0.02M
Total cash from operating activities -1.41408M -1.40945M -2.51386M -0.76521M -2.78184M
Issuance of capital stock 2.20M 1.60M 1.07M 0.66M 0.42M
Depreciation 0.00147M 0.00084M 0.00115M 0.00157M 0.00217M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - -0.30023M 0.30M -0.84649M -
Change to account receivables 0.04M -0.02093M 0.00238M -0.01172M 0.03M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - 2.70M 0.15M 0.83M
Change to netincome - - 1.88M -0.10247M -0.22476M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.03M 0.27M -0.32424M 0.92M 0.44M
Stock based compensation 0.28M 0.07M 0.47M 0.00340M 0.03M
Other non cash items -1.08542M -1.59078M 0.56M -0.28115M -0.28507M
Free cash flow -1.41408M -1.40945M -2.51386M -0.76521M -2.78184M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RP
RepliCel Life Sciences Inc		 - -% 0.01 - - 3.68 - 3.70 -2.7815
SHRX
Sharp Therapeutics Corp.		 - -% 1.00 - - - 32.37
NRX
NurExone Biologic Inc.		 -0.01 1.79% 0.55 - 6.90 - 15.26 -7.2365
MIR
MedMira Inc		 - -% 0.07 - - 223.37 - 293.42 -80.0318
TTI
Thiogenesis Therapeutics Corp.		 - -% 0.56 - - - 15.17 -58.1577

Reports Covered

Stock Research & News

View All

Profile

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. The company has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01, RCT-01, and DermaPrecise. RepliCel Life Sciences Inc. is based in Vancouver, Canada.

RepliCel Life Sciences Inc

570 Granville Street, Vancouver, BC, Canada, V6C 3P1

Key Executives

Name Title Year Born
Mr. Andrew Schutte Pres, CEO & Director 1990
Dr. Kevin John McElwee Ph.D. Co-Founder & Chief Scientific Officer 1970
Mr. Simon S. Ma B.A., CPA, CA Chief Financial Officer 1965
Dr. Rolf Hoffmann M.D. Chief Medical Officer & Member of Clinical Advisory Board 1962
Mr. R. Lee Buckler B.Ed., L.L.B., LLB Corp. Sec. & Director 1966
Ben Austring Chief Legal Officer & Operations Mang. NA
Mr. Darrell Panich M.Sc, PMP, CPM Clinical Consultant 1972
Mr. Andrew Schutte President, CEO & Director 1990
Mr. Ben Austring Chief Legal Officer, Corporate Secretary & COO NA
Mr. David Kwok CPA Chief Financial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.